Replies to post #537397 on NorthWest Biotherapeutics Inc (NWBO)

[dr_lowenstein]

hmmmmm, well first JAMA and any other journal would simply [ront what the authors said, In this case let look at what Dr Bosch said:

A crossover option was included in the Trial design on demand of patients and investigators, and was
necessary to enable recruitment and retention of patients when the Trial began 13 years ago in
2007.

interesting eh???